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Renal abnormalities in sickle cell disease. Sickle cell nephropa- tions for both pre–end-stage renal disease (ESRD) and
thy is indicated by sickled erythrocytes, with the consequent ESRD.
effects of decreased medullary blood flow, ischemia, microinf-
arct and papillary necrosis. Impaired urinary concentrating
ability, renal acidification, hematuria, and potassium secretion RENAL PATHOPHYSIOLOGIC CHANGES
are also found. There may be a causal relationship between ASSOCIATED WITH SICKLE CELL ANEMIAan increase in nitric oxide synthesis and experimental sickle
cell nephropathy, and some studies have indicated that the Table 1 summarizes the numerous pathophysiologic
progression of sickle cell nephropathy is hemodynamically me- changes of the kidneys in patients with sickle cell disorders.
diated. Although there are many studies showing that protein-
uria, nephrotic syndrome, chronic progressive renal failure, Renal tubular disease
and acute renal failure syndromes are the outcome of this
The hypoxic, acidotic, and hyperosmolar environmentdisease, the pathogenic mechanism(s) and potential therapies
remain to be elucidated. Survival of patients with sickle cell ne- of the inner medulla are known to promote sickling of
phropathy who progress to end-stage renal disease (ESRD) is erythrocytes with resultant impairment in renal medul-
equal to non-diabetic ESRD patients, and graft survival rates lary blood flow, ischemia, microinfarct, and papillary
are also similar for those who undergo renal transplantation.
necrosis. Microradioangiographic studies in patients withThis article presents a historical review of the glomerular and
sickle cell disease showed a significantly reduced numbertubular disorders associated with sickle cell nephropathy, and
reviews therapeutic indications to slow its progression. Further of vasa recta, abnormal dilation, or obliteration of the
research is needed. remaining medullary capillaries with consequent loss in
the countercurrent multiplication and exchange system
of the inner medulla [3, 4]. Clinically, patients demon-
Sickle cell disease may result in both renal functional strate an inability to concentrate urine. In young children
disturbances and anatomical alterations. The description with sickle cell anemia (SCA), it has been observed that
of renal complications spans this century, starting with maximal urine osmolality can be increased by multiple
“increased urine volume of low specific gravity” by Her- blood transfusions. However, with repeated sludging
rick in 1910, who was also the first to describe sickle cell causing thrombosis, progressive infarction, and necrosis
disease [1]. With the increasing longevity of patients with of the papillae and inner medulla, the capacity to improve
sickle cell disease, Davis, Mostofi, and Sesterhenn in 1995 renal concentrating ability is progressively lost with age,
reported renal medullary carcinoma as “another example and the defect is irreversible after the age of 15 [4–6].
of renal disease associated with sickle cell disorders” [2]. Maximum urinary osmolality of 400 to 450 mOsm/kg is
This review provides an overview of the spectrum of typically seen under water-deprived conditions in adult
renal abnormalities encountered in sickle cell nephropa- patients with SCA. In heterozygotes, more gradual and
thy, possible mechanisms involved, and treatment op- smaller degrees of impairment are seen [4–6].
In addition to defects in urinary concentrating ability,
other renal functions that are primarily accomplishedKey words: sickle cell nephropathy, renal disease, end-stage renal
in the renal medulla, including renal acidification anddisease, African American, anemia, urinary concentrating ability,
hemodynamics. potassium secretion, are also found to be impaired in
sickle cell patients. The former is manifested as an incom-Received for publication February 15, 1999
plete form of distal renal tubular acidosis (RTA). Underand in revised form May 13, 1999
Accepted for publication June 14, 1999 normal conditions, these patients do not manifest acido-
sis; however, in the setting of mild renal insufficiency, 2000 by the International Society of Nephrology
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Table 1. Renal syndromes and functional abnormalities in sickle normal. This is evidenced by an increased reabsorption
cell disorders
of phosphorus and b-microglobulins and increased secre-
Abnormality Comments References tion of uric acid and creatinine [4, 13].
Hematuria 10% bilateral, left 43 more than [6, 27, 28]
right Abnormalities of renal hemodynamics
Proteinuria High association with increased [30, 40]
Alterations in renal hemodynamics were noted inage
Increased glomerular ? prostaglandin mediated, [15, 16, 24] sickle cell disease patients but not in subjects with the
filtration (GFR) ? nitric oxide sickle cell trait. Increased glomerular filtration rate (GFR)
Increased renal ? prostaglandin mediated [15, 16]
and renal plasma flow (RPF) have been well describedplasma flow
Acute renal failure Case reports; occurring in the [46–49] in patients with sickle cell disease [14–16] putatively re-
setting of precipitating factors lated to compensatory hypersecretion of vasodilator pros-
Chronic renal Severity appeared to be age- [29–31]
taglandins in response to sickling. Indomethacin treat-insufficiency related
Decreased concen- Uosm 400–450 mOsm/kg under [4–6] ment has been shown to produce significant decreases in
trating ability water deprivation GFR in these patients but not in control subjects [15, 16].
Renal tubular Incomplete form of RTA [7–10]
Both GFR and RPF are normal during adolescence butacidosis (RTA)
Impaired potassium Aldosterone independent [8, 13] are frequently subnormal after the age of 40 [17, 18].
secretion Progressive renal insufficiency in these patients has been
Increased glomerular Size selectivity defect found in [21]
ascribed to hyperfiltration-mediated sclerosis of the glo-permselectivity patients with renal insufficiency
Altered ultrafiltra- ? Variable with GFR [21, 23] merular capillaries [19, 20]. In a recent study to deter-
tion coefficient mine the cause of progressive renal insufficiency in pa-
tients with SCA, Guasch, Cua, and Mitch found an
association between renal insufficiency and a decrease
in ultrafiltration coefficient [21]. In addition, there is
hyperchloremic metabolic acidosis has been described an inverse correlation between ultrafiltration coefficient
[7]. Sickle cell patients are unable to lower their urine and glomerular permselectivity, as assessed by the frac-
pH to less than 5.3 following ammonium chloride loading tional clearances of albumin and IgG. It is of interest
[8, 9]. A blunted increase in urinary excretion of titrat- that the ultrafiltration coefficient was also found to be
able acid in these patients compared with control sub- reduced in albuminuric patients with normal GFR. This
jects has been shown by different investigators [8–10]. latter finding appears to support the observation of Pow-
Ammonium excretion was found to be either normal or ars et al that proteinuria and the nephrotic syndrome
decreased [8, 10]. This is not seen in patients with the were significant preazotemic predictors of chronic renal
sickle cell trait [11]. failure [22]. In a more recent study, Schmitt et al found
Hyperkalemia has not been reported to occur in sickle enhanced macromolecule trafficking, decreased glomer-
cell disease patients unless there is renal function impair- ular size selectivity, and a dramatic increase in ultrafil-
ment [7, 8] or stress such as volume contraction during tration coefficient (Kf) in proteinuric patients with SCA
a sickle cell crisis [7]. Like the urinary acidification de- [23]. Although the latter finding seems to be in apparent
fect, the defect in potassium secretion is not clinically contradiction to the results obtained by Guasch et al,
apparent under normal conditions. De Fronzo et al have Schmitt et al argued that the patients studied by Guasch
demonstrated impaired potassium secretion in the pres- et al had more advanced glomerular dysfunction, includ-
ence of an intact renin-aldosterone axis, suggesting the ing a lower mean GFR and a higher degree of protein-
presence of a primary defect in the renal tubular secre- uria. The authors speculated that proteinuria and an
tion of potassium [8]. It is probable that the abnormality increase in Kf may represent very early changes that act
in potassium metabolism could be due to the result of synergistically to trigger the development of glomerulo-
ischemic damage to the segment of the distal nephron sclerosis. At later stages, these early changes are no
responsible for potassium excretion; however, the exact longer detected, and even a decrease in Kf may contrib-
mechanism of decreased potassium excretion has not ute to the decrease in GFR [23].
been well elucidated. Selective aldosterone deficiency Of interest, over the past few decades since the discov-
as well as reports of hyporeninemia hypoaldosteronism eries of the multifold functions of nitric oxide (NO) in
have been described [7, 12]. Despite impaired potassium animal and human physiology, the causal relationship
secretion, the serum potassium level does not increase between increase NO synthesis and glomerular hyperfil-
during potassium loading. This finding suggests an in- tration has been described in experimental models of
creased intracellular shift of potassium, probably caused sickle cell nephropathy. Bank et al have shown that in-
by b2 adrenergic stimulation [13]. ducible NO synthase (NOS II) is increased in the glomer-
In contrast to defects in distal nephron abnormalities, uli and distal nephron of transgenic sickle cell mice but
not in control mice [24]. The investigators further dem-proximal tubular functions were found to be supra-
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onstrated that urinary excretion of the products of NO RENAL ANATOMIC AND PATHOLOGIC
FINDINGS ASSOCIATED WITH SICKLE(NO2S 1 NO3) and GFR is significantly higher in the
CELL ANEMIAtransgenic sickle cell mouse model compared with con-
trols. It is hypothesized that NOS II may increase the Table 2 summarizes the major anatomic and patho-
synthesis of NO leading to vasodilation, which, in turn, logic (morphologic) changes of the kidneys occurring in
may contribute to renal hyperperfusion. In a more recent sickle cell disease patients. Structural changes were first
study by the same group of investigators, the exposure described in 1923 by Sydenstricker, Mulherin, and Hou-
of the transgenic sickle cell mice to chronic hypoxia has seal, who observed prominent glomeruli distended with
led to several important observations [25]. Specifically, blood, as well as necrosis and pigmentation of tubular
the authors have shown that hypoxia could result in cells [32]. Subsequent studies by Bernstein and Whitten
in 1960 [33] and Buckalew and Someren in 1974 [34]inducible NO synthase (iNOS) activation, superoxide
stressed that glomerular enlargement and congestionradical and peroxynitrite (ONOO2) formation. Two con-
were more frequent in children older than two years oldsequences of these reactions appear to be nitration of
and were most marked in the juxtamedullary glomeruli.tyrosine residues of some renal proteins and enhanced
Elfenbein et al observed that glomeruli of patients withapoptosis ultimately leading to structural damage. Ische-
sickle cell disease were 87% larger than controls andmia/reperfusion-mediated apoptosis has previously been
74% larger than those of patients with sickle cell traitshown to induce tubulointerstitial changes, loss of func-
[35]. Similar findings were observed by Falk et al [29]tioning nephrons, and eventual scarring.
and Bathena and Sondheimer [36].
Hematuria Other prominent lesions found in the renal medulla
consist of focal scarring, interstitial fibrosis, tubular atro-Hematuria is a common finding in both sickle cell trait
phy, and infiltration with lymphoid cells. Iron depositsand disease. Abel and Brown first described the relation-
primarily in the proximal tubule are common findings,ship between sickle cell disease and hematuria in 1948
and pigment casts may be seen [3, 37].[26]. The cause of the hematuria is probably related to
The distinctive abnormalities of the renal medulla andthe pathologic events in the inner medulla and renal
papillae in sickle cell nephropathy are due to occlusionpapillae of patients with sickle cell disease. Sickling of
of blood flow in the vasa recta, which may lead to medul-erythrocytes in the vasa recta results in increased blood
lary and papillary necrosis and fibrosis [3, 4, 37]. Anviscosity, microthrombi formation, and ischemic necro-
extensive review by Vaamonde shows that renal papil-sis, which, in turn, could cause structural changes leading
lary necrosis is a frequent complication of sickle cellto hematuria [4, 6]. In 21 sickle cell kidneys removed
nephropathy in homozygotes, as well as in heterozygotes,because of protracted hematuria and the possibility of
and has an incidence ranging from 15 to 36% [37]. Itsrenal neoplasm, Mostofi et al found severe stasis in peri-
development is generally a clinically silent and slowlytubular capillaries that were most marked in the medulla
progressive process because of recurrent, subacute sick-
[27]. Extravasation of blood predominantly in the col-
ling in the renal medulla. It is most frequently discovered
lecting tubules was observed. Hematuria may originate as an incidental finding during renal radiography in
from either kidney, although a preponderance of left- asymptomatic sickle cell patients. Renal cortical infarc-
sided renal bleeding has been observed [6, 27, 28]. tions with subsequent renal cortical scarring have been
observed. The infarcted areas are usually small, and renalProteinuria
function generally is not affected.
Unlike hematuria, proteinuria is more commonly en- Structural glomerular abnormalities are seen in patients
countered in patients with homozygous (hemoglobin SS) with SCA but not in heterozygotes. The morphologic
sickle cell disease than in other hemoglobinopathies [29]. lesions most frequently identified are focal segmental
Proteinuria occurred in 20 to 30% of patients with sickle glomerulosclerosis (FSGS) and membranoproliferative
cell disease [30], although a higher incidence has also glomerulonephritis-like (MPGN-like) disease without im-
been reported. Nephrotic syndrome is now well recog- mune complex deposits. Definite immune-complex de-
nized, although its frequency in sickle cell nephropathy posits or MPGN type I were documented in only 12 cases
has not been well studied. Renal failure occurs with high in the literature [38, 39]. More recently, Davis, Mostofi,
frequency in patients with nephrotic syndrome [31]. A and Sesterhenn described 34 cases of renal medullary
prospective study by Powars et al showed that ineffective carcinoma, termed “the seventh sickle cell nephropathy”
erythropoiesis with increasingly severe anemia, hyper- [2]. All of these patients were believed to have sickle
tension, proteinuria, the nephrotic syndrome, and micro- cell trait, except for one who had hemoglobin sickle cell
scopic hematuria was a significant preazotemic predictor disease. This is a highly aggressive neoplasm that had
usually metastasized at the time of diagnosis. The authorsof chronic renal failure [22].
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Table 2. Pathologic findings in sickle cell anemia
Abnormality Comments References
Glomerular enlargement More frequent in children over 2 years of age [29, 33, 34]
Most marked in juxtaglomerular glomeruli
Hemosiderin deposits No definite correlation between the amount of these deposits [33, 41]
to the presence of renal disease
Papillary necrosis [3, 4, 37]
Cortical infarction Well documented but seldom reported [4]
Focal segmental glomerulosclerosis ? Hyperfiltration-mediated [19, 29, 30, 36]
MPGN type I 12 cases identified in the literature [38, 39]
MPGN without deposits [31, 35, 41]
Tubular atrophy, interstitial fibrosis [3, 4, 35]
Medullary carcinoma Occurring on the same side as hematuria [2]
Increased glomerular membrane pore radius ? Intrinsic glomerular capillary injury [21, 23]
felt that these tumors probably arise in the calyceal epi- spite these observations, Falk and Jennette challenged
thelium in or near the renal papillae on the same side the analogy made by McCoy because iron generally de-
of hematuria. posits in the interstitium and along the lower nephron
rather than in the glomeruli per se [30]. In particular,
glomerular lesions similar to those occurring in sicklePATHOGENESIS OF RENAL INSUFFICIENCY
cell nephropathy are not seen in other conditions ofAND GLOMERULAR LESIONS IN PATIENTS
iron overload, such as in idiopathic hemosiderosis or inWITH SICKLE CELL ANEMIA
patients who receive a large number of red cell transfu-
The mechanisms whereby nephrotic syndrome, renal sions. Thus, it is unlikely that iron overload alone ex-
insufficiency, and glomerular lesions interrelate in patients plains the pathophysiologic mechanism of sickle cell ne-
with sickle cell nephropathy remain unclear. Neverthe- phropathy associated with nephrotic syndrome.
less, several proposed mechanisms include fortuitous oc- Intracapillary fragmentation and phagocytosis of sick-
currence, iron overload and subsequent deposition in led red cells are other suggested mechanisms for the
the kidneys, continued intracapillary fragmentation and MPGN or MPGN-like glomerular lesions seen in sickle
phagocytosis of sickled red cells, immune complex for- cell nephropathy [35]. Elfenbein and later Bakir et al
mations, FSGS associated with glomerular hyperfiltra-
speculated that small fragmented red cell masses may
tion, and/or intrinsic glomerular capillary injury.
become lodged in isolated capillary loops and are contin-It is unlikely that the association of nephrotic syn-
uously phagocytosed by mesangial cells [31, 35]. Thedrome and sickle cell disease is fortuitous in view of a
resultant “active mesangium” simultaneously lays downhigh prevalence of proteinuria (20 to 30%) and nephrotic
new basement membrane material beneath the endothe-syndrome (4%) in one series [31]. In addition, it has
lium of the capillary loop, giving rise to the reduplicatedbeen shown that there is a high degree of association
appearance. Inducing intravascular fibrin formation re-between proteinuria, chronic renal insufficiency, and in-
sulted in similar lesions in rat models [42]. Vitsky et alcreased age. Moreover, the severity of renal insufficiency
described virtually identical lesions in human patientswas found to be age related [40].
with the hemolytic uremic syndrome who were biopsiedSimilar alterations in renal ultrastructures of nephrotic
during the healing phase [43].cases associated with sickle cell disease and the nephrotic
Autologous immune complex formation is yet anothersyndrome developed in rabbits following prolonged in-
suggested pathogenic mechanism of sickle cell glomeru-travenous injection of saccharated iron oxide complexes
lopathy. Pardo et al demonstrated the localization of im-led McCoy to speculate that iron overload and possibly
munoglobulin, complement components (of the classiccirculating iron-protein complexes are responsible for
pathway), and renal tubular epithelial antigen in a granu-the glomerular lesion(s) observed [41]. Under both con-
lar pattern along the glomerular basement membraneditions, light microscopy showed atrophy and collapse
[39]. In addition, cryoprecipitate complexes of renal tu-of the renal parenchyma with accumulations of pigmen-
bular epithelial antigen-antibody to renal tubular antigentations that stained positive for iron in the glomeruli as
as well as antibody to renal tubular antigen were detectedwell as in the tubular epithelium. Electron microscopy
in the circulation of some patients. Although these find-confirmed the presence of electron-dense bodies that
ings appear attractive, immune complex injury has beenare considered to represent iron complexes in lysosomal
documented in only 12 cases in the literature [38, 39].structures in all glomerular components but primarily
The association between hyperfiltration accompaniedin the mesangium. This material was also present in
intracellular locations in the tubular epithelial cells. De- by glomerular hypertrophy, proteinuria, morphologic
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changes of FSGS, and renal insufficiency has led many and kidney in the face of severe painful crises has been
described [48]. We have recently described a case ofinvestigators to incriminate that renal insufficiency in
patients with sickle cell disease is primarily hemodynami- postpartum exacerbation of sickle cell nephropathy man-
ifested by nephrotic syndrome and declining renalcally mediated. More recently, however, Guasch et al
suspect intrinsic glomerular capillary injury as a distinct function [49]. In our case, it is speculated that the hemo-
dynamic “stress” of pregnancy superimposed on a back-pathogenic mechanism of sickle cell glomerulopathy [44].
Assuming an “isoporous and shunt” model of the glo- ground of substantial chronic nephron loss may have
exaggerated the clinical expression of sickle cell ne-merular capillary wall, the authors found an increase in
the restrictive (isoporous) pore size associated with in- phropathy. Although the mechanism of acute renal fail-
ure in patients with sickle cell disease is far from under-creased fractional clearances of all dextrans (26 to 64 A˚)
in SCA patients compared with healthy control subjects. stood, “syndromes” appear to occur in the presence of
precipitating factors.Of interest, in the subset of SCA patients who develop
renal insufficiency, the total number of restrictive pores
was reduced more than 70%, whereas the shunt parame-
TREATMENT
ter increased twofold. This is accompanied by the selec-
There has been ample literature on the clinical mani-tive passage of large dextrans in SCA patients who de-
festations of sickle cell nephropathy. Proteinuria, ne-velop renal insufficiency compared with values from SCA
phrotic syndrome, chronic progressive renal failure lead-controls and healthy controls. These findings suggest that
ing to ESRD, and even syndromes of acute renal failurethe size-selectivity defect occurs in patients who develop
have been reported with increasing frequency. Unfortu-renal insufficiency. Subsequent studies by Schmitt et al
nately, the pathogenic mechanisms of sickle cell ne-also revealed significant increase in the fractional clear-
phropathy and their therapeutic implications remain toances of neutral dextrans in the 14 SCA patients com-
be elucidated. Isolated reports showed no consistent ben-pared with 16 age- and sex-matched healthy controls for
efits of nonsteroidal anti-inflammatory drugs (NSAIDs)all radius ranges studied [23]. Further analysis of dextran
or immunosuppressive drugs such as steroids and/or cy-transport through a heteroporous membrane model
clophosphamide in the management of sickle cell ne-showed a slight increase in the mean radius of restrictive
phropathy [39, 41, 50]. Short-term angiotensin-convert-pores in agreement with earlier reports by Guasch et al
ing enzyme inhibitor (ACEI) treatment with enalapril[44]. In contradiction to Guasch, however, Schmitt et al
has been shown to result in reduction in proteinuria infound an increase in ultrafiltration coefficient (Kf) [23].
10 selected patients with mild renal insufficiency andThe authors propose that glomerular hypertrophy could
biopsy documented prevalence of glomerular enlarge-promote podocyte stretch lesions, enhance transglomer-
ment and perihilar FSGS [29]; however, there was anular trafficking of macromolecules both via decrease in
increase in proteinuria after discontinuation of enalapril.size selectivity and increase in Kf ultimately leading to
Whether angiotensin II receptor blocker (ARB) has athe development of FSGS.
salutary effect in reducing proteinuria in sickle cell ne-Genetic studies of SCA have suggested that the coin-
phropathy has not been studied. Data on the effects ofheritance of microdeletions in one or two of the four
ACEI and ARB on proteinuria and the progression toa-globin genes (a-thalassemia) may be renoprotective
renal failure among patients with sickle cell nephropathybecause they are associated with a lower prevalence of
are still limited and need to be evaluated further, asmacroalbuminuria and lower mean arterial pressure com-
there is now compelling evidence that, in general, pro-pared with patients with intact a-globin genes. The mech-
teinuria is associated with a more rapid decline of renalanisms involved are unclear but are thought to be related
function [51]. In addition, the long-term effects of ACEIto a reduced mean corpuscular volume or to a lower
or ARB in terms of alterations in intraglomerular hemo-erythrocyte hemoglobin concentration. Similar studies
dynamics and potential reversal of the effects of earlyrevealed no association between b-globin gene haplo-
FSGS associated with sickle cell disease have not beentypes and albuminuria [45].
reported. In different rat models of FSGS, the protective
Syndromes of acute renal failure effect of ACEI or ARB against proteinuria may occur
independent of hemodynamic changes, whereas theAlthough the literature on acute renal failure in the
long-term effect of ACEI or ARB on histologic alter-setting of sickle cell crisis is scanty, episodes were most
ations appears to be dependent on systemic and intrag-commonly noted in cases of overwhelming sepsis, high
lomerular pressure control. In spontaneously hyperten-fever, and/or nontraumatic rhabdomyolysis [46–48]. In
sive rats with adriamycin nephropathy, captopril haseach instance, massive generalized sickling of erythro-
been shown to reduce mesangial expansion and glomeru-cytes occur. In fact, it appears that no organ system is
losclerosis [52]. In rats with 5/6 renal mass ablation, ena-spared from the effect of hypoxia, acidosis, and impaired
rheology. Acute multiorgan failure involving lung, liver, lapril, losartan, or combination therapy revealed a high
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correlation between blood pressure and the extent of Patient survival in sickle cell nephropathy recipients was
significantly lower than that of others both at one yearFSGS and no differences in the frequency of FSGS
within groups of similar blood pressure [53]. The latter (sickle cell nephropathy 78% vs. other ESRD 90%) and
at three years (sickle cell nephropathy 59% vs. otherfinding is in agreement with previous studies showing
that the protective effect of enalapril against the develop- ESRD 81%). Nevertheless, further analysis revealed a
trend toward better patient survival with renal trans-ment of FSGS is governed by the reduction in both
systemic and glomerular hypertension in uninephrec- plantation compared with wait-listed sickle cell nephrop-
athy patients on maintenance hemodialysis. The authortomized fawn-hooded rats [54]. In light of the possible
development of hyperkalemia in a subset of patients suggested that these encouraging results should be taken
into account when offering renal replacement therapydiscussed previously in this article, the use of ACEI and
ARB should be used with caution, especially in those to patients with end-stage sickle cell nephropathy. It was
further argued that the high mortality rates observed inwith renal insufficiency.
Both maintenance hemodialysis and renal transplanta- sickle cell nephropathy transplant recipients probably
resulted from the underlying disease itself rather than antion have been shown to be viable options for patients
with sickle cell nephropathy who progress to ESRD. adverse impact of renal transplantation. In Ojo’s series,
sickle cell nephropathy transplant recipients had a me-Survival of patients on hemodialysis has been shown to
be equivalent to other nondiabetic ESRD patients [55]. dian survival rate of 33 months. A mortality rate of up
to 50% at two years has been reported in sickle cellRenal transplantation is used less frequently, possibly
reflecting the limited experience with renal transplanta- disease patients with established renal failure and/or ne-
phrotic syndrome [31]. Despite encouraging results ontion in this patient population. In two sequential national
surveys conducted by Chatterjee, short-term patient and survival advantage of renal transplantation over mainte-
nance hemodialysis, renal transplantation in sickle cellallograft survival in patients with sickle cell hemoglobin-
opathies (sickle cell disease or trait) were found to be disease is not without morbidity. An increase in the fre-
quency of crisis has been demonstrated in patients whocomparable to those of nonsickle recipient population.
The initial survey was reported in 1980 and involved underwent a successful kidney transplantation [56, 57,
59, 60]. This appears to be due to increased endogenous34 renal transplants performed in 30 patients. One-year
patient and graft survival was 87 and 67%, respectively hematopoiesis with a consequent increase in blood vis-
cosity and vaso-occlusive crisis. Painful sickle cell crisis[56]. In an update registry in 1987, data recollected from
45 renal transplants performed in 40 recipients revealed associated with the use of the monoclonal antibody
OKT3 has been described [60]. Recurrent sickle cella one-year patient survival rate of 88%. The graft sur-
vival rate at one year was 82% in living donor transplant nephropathy in transplant kidney 3.5 and 4.5 years post-
transplantation has been reported [60, 61]. These latterrecipients and 62% in cadaveric transplant recipients
[57]. From these studies, the author concluded that sickle factors were not analyzed in Ojo’s series. Whether pa-
tients with ESRD secondary to sickle cell nephropathycell disease or trait should not be regarded as a contrain-
dication to transplantation, at least from the patient and should receive hemodialysis or kidney transplantation
remains an unresolved issue and may depend on centerallograft survival standpoint. Recently, Ojo et al pub-
lished the results of patient and allograft outcomes in experience(s). However, with the important advances
in immunosuppressive therapy that may translate intorenal transplant recipients with ESRD secondary to
sickle cell nephropathy compared to age-matched Afri- better long-term outcomes in organ transplantation, phy-
sicians caring for patients with end-stage sickle cellcan American transplant recipients with ESRD from all
other causes [58]. The study represents the largest series nephropathy should consider renal transplantation as a
feasible treatment option. Bone marrow transplantationreported and consisted of 22,647 African American end-
stage sickle cell nephropathy patients who received kid- has recently emerged as a novel treatment for SCA.
Anecdotal reports suggest a beneficial effect of boneney alone transplant between 1984 and 1996, identified
through the United Network of Organ Sharing (UNOS). marrow transplantation in improving target organ dam-
age, including chronic lung, bone, and central nervousOf these, 82 (0.4%) patients had sickle cell nephropathy
as the primary cause of ESRD. Eighty-one patients had system disease [62]. Whether bone marrow transplanta-
tion in the early stage of the disease can reverse or halthomozygous hemoglobin S(Hb-SS), and one had double
heterozygous hemoglobin sickle cell disease (Hb-SC). the progression of established sickle cell nephropathy is
unknown and awaits clinical studies.One-year graft survival in recipients with end-stage sickle
cell nephropathy was found to be similar to that obtained In summary, a historical view on the proposed patho-
genic mechanisms of glomerular and tubular disordersin other causes of ESRD (sickle cell nephropathy 78%
vs. other ESRD 77%). However, the three-year cadav- associated with sickle cell disease, as well as their thera-
peutic implications and management, have been pre-eric graft survival was diminished among patients with
sickle cell nephropathy (48% vs. other ESRD 60%). sented.
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